In the BioHarmony Drug Report Database
Elagolix
Orilissa (elagolix) is a small molecule pharmaceutical. Elagolix was first approved as Orilissa on 2018-07-23. It is used to treat abdominal pain in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor. Orilissa’s patents are valid until 2036-09-01 (FDA).
Trade Name
|
Orilissa |
|---|---|
Common Name
|
elagolix |
ChEMBL ID
|
CHEMBL1208155 |
Indication
|
abdominal pain |
Drug Class
|
Gnrh receptor antagonists (nonpeptide) |
Image (chem structure or protein)